In a hospital setting, it is common to encounter certain haematological emergencies irrespective of whether or not the patient has an underlying haematological condition or if the hospital has a well-established haematology service. This article aims to define and illustrate common and less common haematological emergencies that a physician may encounter on the wards and the appropriate initial management for the patient prior to a formal hematological consult.
INTRODUCTION
In a hospital setting, it is common to encounter certain haematological emergencies irrespective of whether or not the patient has an underlying haematological condition or if the hospital has a haematology service. This article aims to define and illustrate common and less common haematological emergencies that a physician may encounter on the wards and the appropriate initial management for the patient prior to a formal haematological consult.
TUMOUR LYSIS SYNDROME
This is a haematologic emergency in which cellular contents are released from cells that are lysing, which results in a series of metabolic derangements. Risk factors for severe tumour lysis syndrome include high tumour burden, high total white count >100×10 9 g/dL, high sensitivity to chemotherapy and existing renal impairment 1 .
Tumour lysis can be divided into primary and secondary types. In primary tumour lysis, the onset is before any initiation of treatment or chemotherapy. In secondary tumour lysis, the event occurs after chemotherapy has been initiated 2 .
The Cairo-Bishop definition of tumour lysis is as follows: at least two laboratory features occurring within three days before or seven days after starting chemotherapy, which include high uric acid, high potassium, high phosphate, or low corrected calcium. In addition there has to be at least one clinical feature of either serum creatinine >1.5 upper limit of normal, cardiac arrhythmias or seizures 3 .
Prevention of tumour lysis is important especially in newly diagnosed leukaemias with high total white count, or in lymphomas with high lactate dehydrogenase (LDH) levels. Prevention entails starting the patient on adequate hydration e.g. intravenous (IV) dextrose saline 3-5 L/day. Ensure strict fluid input and output monitoring to achieve urine output of at least 100 ml/hr 4 Urinary alkalinisation for tumour lysis prevention is not currently routinely recommended and is controversial. In the past, the use of sodium bicarbonate to alkalinise urine to pH >6.5 was recommended to convert uric acid to more soluble urate salt, reducing the tendency of uric acid precipitation in the renal tubules 5 . However, the use of sodium bicarbonate is controversial as the maximum solubility of urate occurs at pH 7.5 and at alkaline urine pH, the solubility of xanthine and hypoxanthine decreases, leading to urinary xanthine crystals during and after allopurinol therapy. Alkaline urine may also cause calcium phosphate precipitation in patients with increased phosphate levels 6 . There is also no data showing that urinary alkalinisation is efficacious and that hydration with saline alone is just as effective in minimising uric acid precipitation 6 . The use of sodium bicarbonate should be limited to patients with metabolic acidosis and if used should be promptly discontinued when patient develops or has hyperphosphataemia 3 .
Aggressive electrolyte correction and lowering elevated uric acid levels with either allopurinol 300 mg daily or in certain cases giving IV rasburicase 0.2 mg/kg in 50 ml NS over 30 mins 1 . Rasburicase is more effective in lowering uric acid levels rapidly by increasing renal excretion of uric acid as compared to allopurinol which may take up to 2-3 days to work. Rasburicase is a recombinant urate oxidase which catabolises uric acid to water soluble allantoin which is then really excreted. In patients who are at very high risk of tumour lysis, the use of rasburicase is strongly recommended as allopurinol and hydration alone may not be sufficient. However the attending doctor needs to note the patient's glucose-6-phosphate dehydrogenase (G6PD) status as this drug is contraindicated with patients with G6PD deficiency 7 .
With regards to correcting electrolytes, calcium replacement should only be initiated in the setting of symptomatic hypocalcaemia, as there is concern of calcium-phosphate crystallisation and subsequent nephropathy 1 . Dialysis may be needed if there is severe electrolyte derangement or oliguric renal failure.
It is important to continue to monitor electrolytes and renal function, the tumour lysis panel (potassium, phosphate, calcium, LDH, creatinine) should be monitored closely about 2-3 times a day until the patient stabilises.
HYPERVISCOSITY SYNDROME
Hyperviscosity occurs in the presence of high cell counts or if abnormally high amounts of plasma proteins are found in the blood. It occurs due to sludging and accumulation of cells, blasts or plasma proteins in the microcirculation. Risk factors for hyperviscosity include polycythaemia, hyperleukocytosis (acute myeloid leukaemias with white count >100×10 9 g/dL or leukaemias with high blast counts or monocytosis), Waldenstrom's macroglobulinaemia (especially cases with high IgM) and IgA multiple myeloma (IgA forms multimers) 8 . Symptoms of hyperviscosity can occur in the form of respiratory complaints e.g. breathlessness, hypoxia; neurologic complaints e.g. headaches, visual changes, drowsiness. A fundoscopic exam may reveal papilloedema, dilated blood vessels or retinal haemorrhages.
Treatment of hyperviscosity includes aggressive IV hydration and treatment of the underlying disease with chemotherapy as appropriate. Hydrate with IV normal saline and alkalinise urine. Hydroxyurea 2 g stat and 1-2 g three times daily (tds) can be started on initial presentation for cytoreduction in leukocytosis. Leukapheresis and plasmapheresis can be used as an interim measure to decrease cell counts and plasma protein volume 9 . Venesection can be performed in the setting of polycythaemia (when haematocrit >45%). It is also important to note that blood transfusions should be avoided in the setting of hyperviscosity as it may aggravate the condition 9 .
HYPERCALCAEMIA

Hypercalcaemia
can occur in certain haematological malignancies such as multiple myeloma. Symptoms of hypercalcaemia include fatigue, muscle weakness, thirst, polyuria and constipation. It may also cause corrected QT (QTc) shortening and cardiac arrhythmias. Treatment of hypercalcaemia includes IV hydration, and the use of bisphosphonates such as pamidronate (90 mg) and zolendronic acid (4 mg) 5 . A reduced dose of IV pamidronate 60 mg should be used in instances of renal impairment. It is also important to monitor the patient's fluid intake and output as hypercalcaemia can lead to acute renal impairment. Other adjuncts in the treatment of hypercalcaemia Proceedings of Singapore Healthcare  Volume 23  Number 1  2014 include calcitionin and frusemide. If patient develops oliguric renal failure, the patient may also need haemodialysis.
SUPERIOR VENA CAVA OBSTRUCTION
Superior vena cava obstruction can often occur in conditions such as lymphoma in which cervical and mediastinal lymph nodes hypertrophy and cause a compressive effect on the superior vena cava. It is important to pick up this condition based on symptoms of breathlessness, facial flushing and oedema. An urgent computed tomography scan should be ordered. In cases of lymphoma, chemotherapy should be initiated as early as possible. Otherwise emergent treatment would include starting IV dexamethasone 4 mg tds after discussion with a haematologist.
BLEEDING
Bleeding complications can be due to platelet qualitative and quantitative abnormalities, clotting factor abnormalities. Some of them may be hereditary and others acquired. Instances of severe bleeding include haematuria, intraarticular bleeding, intracranial haemorrhage and gastrointestinal bleeding. Treatment of bleeding diathesis is mainly based on severity of bleeding.
In instances of bleeding secondary to warfarin and elevated international normalised ratio (INR), the warfarin effect can be quickly reversed by omitting warfarin, administering IV Vitamin K 5-10 mg stat, fresh frozen plasma (FFP) at a dose of 10 ml/kg. Subsequently the INR should be rechecked after 6 hours and daily for the next few days 9 . If bleeding still persists, one may consider starting prothrombin complexes in consultation with a haematologist. Instances where the use of prothrombin complex concentrates are in major bleeds such as intracranial bleeding when rapid and full correction of INR is required.
In the setting of thrombocytopaenia in the absence of bleeding, studies have shown that transfusing platelets only if levels are <10×10 9 g/dL versus a more liberal transfusion strategy does not result in more instances of bleeding. However if bleeding does occur due to thromobocytopaenia, one should initiate platelet transfusions irrespective of platelet count. Another measure would be to start tranexamic acid at 1 g tds. It acts an anti-fibrinolytic agent and prevents further bleeding 8 . One should note that it should not be administered to patients with haematuria as it may cause clots to form in the kidneys and ureters which can potentially cause renal damage.
Massive bleeding is defined when patient needs replacement of one blood volume within 24 hours or replacement of more than 50% blood volume within 3 hours or one unit of packed red blood cells per 10 kg body weight per hour. In patients receiving massive transfusion, it may lead to a coagulopathy due to multiple factors such as dilution of coagulation factors, citrate induced hypocalcemia, hypothermia, acidosis and fibrinolysis. Management would include informing the blood bank to activate the massive transfusion protocol, checking full blood count, prothrombin time (PT), activated thromboplastin time (aPTT), fibrinogen, creatinine, blood gases and blood group. During continuous bleeding aim for a haematocrit above 0.3, platelet count >50×10 9 /L, INR below 1.5, aPTT shorter than 1.5 times of reference value and fibrinogen concentration above 2 g/L. Other supportive measures include keeping the patient warm/avoiding hypothermia, keeping pH >7.1 and correcting hypocalcaemia.
In Singapore, constituents of the massive transfusion protocol 10 include: The use of recombinant activated factor VII (90 μg/kg) can be considered with Pack 3; however the risk of thromboembolic complications needs to be weighed against benefit in each individual situation.
DISSEMINATED INTRAVASCULAR COAGULATION Disseminated intravascular coagulation (DIC)
occurs when there is ongoing activation of coagulation, which can result in thrombosis and bleeding 11 . Causes of DIC include severe infections, obstetric complications e.g. preeclampsia and placenta abruption, trauma, burns, haematologic malignancies such as Proceedings of Singapore Healthcare  Volume 23  Number 1  2014 acute promyelocytic leukaemia (APML) and also solid organ malignancies. Diagnosis of DIC can be made based on lab investigations, namely thrombocytopaenia, prolonged PT and aPTT, decreased fibrinogen, increased fibrin degradation products and D-Dimer. Treatment of DIC involves treatment of the underlying cause. Platelet and FFP transfusions should be avoided unless patient is actively bleeding. In the instance of DIC associated with APML, all-transretinoic acid (ATRA) at 45 mg/ m 2 /day in two divided doses should be started 9 .
INFECTIONS IN THE IMMUNOCOMPROMISED HOST
Patients undergoing chemotherapy may be cytopaenic. This predisposes them to infections. Neutropaenia is defined as absolute neutrophil count <0.5×10 9 /L. In instances of neutropaenic fever, the patient needs to be assessed, septic workup done and started on antibiotics. In the hospital setting, first line antibiotics should be started would be tazocin 4.5 g q6-8h or cefepime 2 g q12h +/− amikacin 15mg/kg daily.
The addition of aminoglycosides such as amikacin as part of empirical coverage for neutropenic sepsis was historically done, but not always necessary upfront. Amikacin has a synergistic effect on multidrug resistant gram negative bacteria with β-lactam antibiotics and gives good Pseudomonas coverage. One should add on amikacin in instances where the patient may be still febrile or have rising procalcitonin while on β-lactam antibiotics. It is important to keep in mind and consider stopping amikacin after 72 hours if blood cultures are negative and patient is stable or if 2-3 sets of procalcitionin values are less than 0.25 9 .
In an appropriate setting e.g. lymphomas, subcutaneous granulocyte colony stimulating factor 300 mg can be started for the patient. In instances where patient is penicillin allergic antibiotic options for neutropaenic fever include starting aztreonam. Intravenous vancomycin 1 g q12h (adjusted according to vancomycin trough) should be started in instances of soft tissue infections, line sepsis and septic shock. Patients with neutropaenic fever and are hypotensive and unstable should be started on carbapenems (e.g. meropenem 1g q8h) upfront to cover for more resistant ESBL gram negative bacteria.
Another instance where the patient can be immunocompromised would be the asplenic patient. Patients with refractory immune thrombocytopenia or in certain cases of haemoglobinopathies may have their spleen removed. In addition to regular vaccines, pneumococcal, Haemophilus influenzae, meningococcal vaccines, IV ceftriaxone 2 g daily should be started promptly for these patients with any suspicious of infection based on local susceptibility data in the local setting.
TRANSFUSION ASSOCIATED LUNG INJURY/ TRANSFUSION ASSOCIATED CIRCULATORY OVERLOAD
Transfusion associated lung injury presents as an acute respiratory distress syndrome with noncardiac acute pulmonary oedema, fever, chills and hypotension within 6 hours of a blood transfusion 12 . This has been attributed to passive transfusion of donor anti-HLA and anti neutrophil antibodies. Blood components with higher plasma components e.g. FFP may carry a higher risk. Incidence is roughly 1 in 10,0000. Mortality rate is about 5%. Recognition of this condition is important. If the blood product is still running, it should be stopped immediately. Immediate resuscitation and ventilatory support should be initiated and patient should be started on mechanical ventilation if required. Studies have shown that in 80% of cases, pulmonary infiltrates should rapidly resolve within 96 hrs of the initial insult.
Transfusion associated circulatory overload is a state of fluid overload due to left ventricular failure associated with dyspnoea, orthopnea, pulmonary and peripheral oedema and hypertension. It is a non immunological reaction that usually occurs within 1-2 hours of initiation of transfusion 12 . It tends to occur more often in elderly patients with diminished cardiac function and in patients with chronic anaemia. Management of this condition would be to recognise it early and administer oxygen and diuretics to the patient similar to management of patients with congestive cardiac failure.
APML DIFFERENTIATION SYNDROME
Differentiation syndrome (DS) is a true haematologic emergency that is life threatening and requires awareness and high index of suspicion. While unique to patients with APML undergoing treatment, it is not uncommon for the on call doctor in the hospital to be called to review such patients.
Differentiation syndrome should be suspected in all patients with APML receiving all-transretinoic acid (ATRA) or arsenic trioxide (ATO) who develop respiratory distress secondary to pulmonary infiltrates and/or pleural or pericardial effusions 13 . It is always prudent to err on the side of caution and to initiate treatment with dexamethasone should there be any suspicion of DS. The condition is life threatening and is very responsive to dexamethasone. Dexamethasone should be started at IV 10 mg 12-hourly to continue until three to five days after resolution of symptoms and signs. With treatment, most patients demonstrate improvement within 12 hours and complete resolution of symptoms within 24 hours, although approximately 5% will not survive [14] [15] [16] .
Differentiation syndrome occurs in about 25% of patients treated with ATRA and has a bimodal pattern of occurrence (46% in the first week and 38% in the third to fourth week of treatment) 17 .The mechanism of this condition is thought to be due to release of inflammatory cytokines from malignant promyelocytes. The condition can manifest as fever, oedema, hypotension, dyspnea, weight gain >5 kg and musculoskeletal pain 18, 19 . The signs and symptoms together with pulmonary infiltrates often lead to the misdiagnosis of DS as pneumonia.
For most cases of DS, ATRA or ATO should be continued, only in severe cases where patients develop progressive renal failure or respiratory compromise requiring mechanical ventilation, ATRA or ATO is then stopped and then restarted when DS has resolved. While not universally practiced, in our local context, oral prednisolone 0.5 mg/kg/day from day one until white blood cells <5×10 9 /L for three consecutive days is given during treatment of APL as prophylaxis for differentiation syndrome. The incidence may be lower when ATRA is administered concurrently with induction chemotherapy or prophylactic glucocorticoids 13, 20 .
